Go To Main content
Unit_Image
Back
Font: S M L
:::

::: Hong-Jaan Wang

🧪 PHARMACEUTICAL SCIENCE
Hong-Jaan Wang
Hong-Jaan Wang
Professor
Dean
📞 Contact Information
Lab：R9304、R9303｜Dean Office：R9354
Tel：+886-2-87923100 ext. 18179, 18849
E-mail： hongjaan@mail.ndmutsgh.edu.tw
🎓 Education
Ph.D., Life Sciences, National Defense Medical Center, 2014
M.S., Pharmacy, National Defense Medical Center, 2003
B.S., Pharmacy, National Defense Medical Center, 1999
🏛 Experience
07/1999–05/2014 Airforce R.O.C.
06/2014–06/2015 Faculty, School of Pharmacy, National Defense Medical Center
07/2015–07/2019 Assistant Professor, School of Pharmacy, National Defense Medical Center
10/2017–03/2018 Visiting Scholar, UCSF (Lab of Leslie Z. Benet)
08/2019–07/2023 Associate Professor, School of Pharmacy, National Defense Medical Center
08/2022–08/2025 Director, School of Pharmacy, National Defense Medical Center
08/2025–present Dean, College of Pharmacy, National Defense Medical University
10/2022–03/2023 Visiting Scholar, Vanderbilt University (Lab of Frederick P. Guengerich)
08/2023–present Professor, School of Pharmacy, National Defense Medical Center
07/2015–06/2020 Scientific Consultant, Sinew Pharma Inc.
01/2017–present Editorial Board, Chinese Pharmacopoeia
01/2019–12/2021 Deputy Convener, Chinese Pharmacopoeia Compilation Advisory Council (General Pharmaceutics Group)
01/2022–present Convener, Chinese Pharmacopoeia Compilation Advisory Council (General Pharmaceutics Group)
07/2022–present Scientific Consultant, TheratOcular Biotek Co.
2023 Evaluation Committee, Pharmacy & Traditional Chinese Medicine Division, Department of Life Sciences, National Science and Technology Council
2025 Evaluation Committee, Pharmacy & Traditional Chinese Medicine Division, Department of Life Sciences, National Science and Technology Council
🔬 Research Interest
Pharmacokinetics and pharmacodynamics, Drug metabolism, Enzyme kinetics
🧾 Publications
(* Corresponding author；Bold First author； Underline Co-author)
  1. HJ Wang, LH Pao, CH Hsiong, TY Shih, MS Lee, OYP Hu*. Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure–activity relationship. AAPS J. 2014 Mar; 16(2):258–268.
  2. HJ Wang, CH Hsiong, ST Ho, MJ Lin, TY Shih, PW Huang, OYP Hu*. Commonly used excipients modulate UDP-glucuronosyltransferase 2B7 activity to improve nalbuphine oral bioavailability in humans. Pharm Res. 2014 Jul; 31(7):1676–1688.
  3. HJ Wang, CH Hsiong, LH Pao, WL Chang, LJ Zhang, MJ Lin, ST Ho, PW Huang, OYP Hu*. New finding of nalbuphine metabolites in men: NMR spectroscopy and UPLC–MS/MS spectrometry assays in a pilot human study. Metabolomics. 2014 Aug; 10(4):709–718.
  4. YF Ueng*, CK Lu, SH Yang, HJ Wang, CC Huang. Potentiation of the anticoagulation effect of warfarin by the herbal remedy shu-jing-hwo-shiee-tang in rats: The dosing regimen and pharmacokinetic interaction. Drug Metab Pharmacokinet. 2017 Feb; 32(1):85–91.
  5. HJ Wang, CK Lu, WS Kuo, WC Chen, YF Ueng*. Shenmai-Yin decreased the clearance of nifedipine in rats: The involvement of time-dependent inhibition of nifedipine oxidation. J Food Drug Anal. 2019 Jan; 27(1):284–294.
  6. WC Chen, PW Huang, WL Yang, YL Chen, YN Shih, HJ Wang*. Fundamentals of pharmacokinetics to assess the correlation between plasma drug concentrations and different blood sampling methods. Pharm Res. 2019 Feb; 36(2):32.
  7. KT Lin, SW Lai, SD Hsu, CY Fan, HJ Wang, PK Chang, WH Liu, YL Chen, IC Yen, SY Lee*. Shoulder pain and risk of developing hypertension and cardiovascular disease: A nationwide population-based cohort study in Taiwan. J Med Sci. 2019 May; 39(3):127–134.
  8. RJ Liang†, YH Lai†, YT Kao, TH Yang, YL Chen, HJ Wang*. A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation. Eur J Med Chem. 2019 Sep; 178:544–551.
  9. YF Ueng†, HJ Wang†, SC Wu, YY Ng*. A practical thrice weekly ertapenem to avoid neurotoxicity in hemodialysis patients. Antimicrob Agents Chemother. 2019 Dec; 63(12):e01427–19.
  10. HJ Wang and LZ Benet*. Protein binding and hepatic clearance: Re-examining the discrimination between models of hepatic clearance with diazepam in the isolated perfused rat liver preparation. Drug Metab Dispos. 2019 Dec; 47(12):1397–1402.
  11. RJ Liang†, YN Shih†, YL Chen, WY Liu, WL Yang, SY Lee, HJ Wang*. A dual system platform for drug metabolism: Nalbuphine as a model compound. Eur J Pharm Sci. 2020 Jan; 141:105093.
  12. JK Sodhi, HJ Wang, LZ Benet*. Are there any experimental perfusion data that preferentially support the dispersion and parallel tube models over the well-stirred model of organ elimination? Drug Metab Dispos. 2020 Jul; 48(7):537–543.
  13. TY Chiang, HJ Wang, YC Wang, ECH Tan, IJ Lee, CH Yun, YF Ueng*. Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats. J Ethnopharmacol. 2021 May; 271:113914.
  14. SH Hsu, AC Cheng, TY Chang, LH Pao, CH Hsiong, HJ Wang*. Precisely adjusting the hepatic clearance of highly extracted drugs using the modified well-stirred model. Biomed Pharmacother. 2021 Sep; 141:111855.
  15. HJ Wang†, ECH Tan†, TY Chiang, WC Chen, CC Shen, YF Ueng*. Effect of repeated Shengmai-San administration on nifedipine pharmacokinetics and the risk/benefit under co-treatment. J Food Drug Anal. 2022 Mar; 30(1):111–127.
  16. RJ Liang, SH Hsu, TY Chang, TY Chiang, HJ Wang*, YF Ueng*. Metabolism-involved drug interactions with traditional Chinese medicine in cardiovascular disease. J Food Drug Anal. 2022 Sep; 30(3):331–356.
  17. TY Chang, HJ Wang, SH Hsu, ML Chang, LT Kao*, LH Pao*. Evidence of the need for modified well-stirred model in in vitro to in vivo extrapolation. Eur J Pharm Sci. 2022 Oct; 177:106268.
  18. HJ Wang, AC Chen, HY Chen, HC Cheng, LT Kao, CK Lu, KC Tsai, IJ Lee, YF Ueng*. Effects of the herbal formula Xin-yi-san on the oxidation and pharmacokinetics of theophylline in rats. J Pharm Pharmacol. 2023 Sep; 75:1225–1236.
  19. SM Glass, Y Tateishi, FP Guengerich, HJ Wang*. 3,4-Desaturation of retinoic acid by cytochrome P450 27C1 prevents P450-mediated catabolism. Arch Biochem Biophys. 2023 Jul; 743:109669.
  20. YL Chen, YH Lai, Eagle YK Huang, HJ Wang*, HY Hung*. Nalbuphine-6-glucuronide is a potent analgesic with superior safety profiles by altering binding affinity and selectivity for mu-/kappa-opioid receptors. Life Sci. 2024 Mar; 340:122441.
  21. HJ Wang and LF Hsu*. The role of partial area under the curve and maximum concentrations in assessing the bioequivalence of long-acting injectable formulation of exenatide: A sensitivity analysis. Eur J Pharm Sci. 2024 Apr; 195:106718.
  22. LT Kao, AC Chan, HJ Wang, YL Wen, CK Lu, CC Liaw, KC Tsai, YF Ueng*. Xin-yi-san contains potent human CYP1A2 inhibitors and its combined use with theophylline in treatment increases adverse risks in patients. Phytomedicine. 2024 May; 131:155760.
  23. SL Tang, MR Sumitra, YC Kuo, HL Hsu, M Ansar, SL Huang, SY Lee, HJ Wang, B Lawal, Alexander TH Wu, LC Chen, HS Huang*. Computer-aided drug discovery of a dual-target inhibitor for ovarian cancer: therapeutic intervention targeting CDK1/TTK signaling pathway and structural insights in the NCI-60. Comput Biol Med. 2025 May; 193:110445.
  24. HC Cheng, HT Chen, HY Chen, NH Chou, HJ Wang, LH Pao, SL Tang*. Advancing hepatic clearance prediction across in vitro, ex situ, and in vivo systems to facilitate in vitro-to-in vivo extrapolation. Eur J Pharm Sci. 2025; 212:107171.
  25. RJ Liang, SH Hsu, HT Chen, WH Chen, HY Fu, HY Chen, HJ Wang*, SL Tang*. Selection of an optimal metabolic model for accurately predicting the hepatic clearance of albumin-binding-sensitive drugs. Pharmaceuticals. 2025; 18:991.
  26. Waiting Tai, HJ Wang, Pancy TH Kwong, Patricia Tang, CC Shih*, HK Chan*. Development of inhalable spray dried nalbuphine hydrochloride powders. Int J Pharm. 2025; 682:125952.
  27. SL Tang, MR Sumitra, LC Chen, FC Liu, HL Hsu, YC Kuo, M Ansar, SL Huang, SY Lee, HJ Wang, B Lawal, ATH Wu, YT Wen, HS Huang*. Machine learning–driven discovery of NSC828779 as a multi-mechanistic NLRP3 inflammasome inhibitor for inflammatory diseases. Comput Biol Med. 2025 May; 197:111110.
💡 Patents
  1. Oliver Yoa-Pu Hu, Hong-Jaan Wang, Cheng-Huei Hsiong, Li-Heng Pao. Cytochrome P450 2C9 inhibitors. 2008, ROC I 299002 (term 2024/4/4).
  2. Oliver Yoa-Pu Hu, Hong-Jaan Wang. New administration route, new oral dosage form and new dose of nalbuphine. 2013, ROC I 397413 (term 2030/10/28).
🧾 Research Projects
※ 可上下捲動瀏覽
  1. The metabolism of kappa receptor agonist and genetic polymorphism studies of its responsible enzyme. (2014/08–2016/07, MOST 103-2320-B-016-007-MY3)
  2. Using different mechanical pain tests in rats to investigate the correlation between pharmacokinetic and pharmacodynamic effects of multimodal analgesics. (2016/01–2016/12, 105A23)
  3. Enzyme kinetic study of opioid analgesic—nalbuphine. (2017/01–2017/12, MAB-106-078)
  4. The study of opioid analgesic—nalbuphine: High-yield chemical synthesis of nalbuphine-3-glucuronide and the active metabolite nalbuphine-6-glucuronide. (2018/01–2018/12, 805-C107-10)
  5. On the basis of pharmacokinetics to assess the correlation between plasma drug concentrations and different blood sampling methods. (2018/04–2019/03, MOST 106-2320-B-016-001)
  6. The divergence of determined blood concentrations of biopharmaceutical drug disposition system class I and IV clinical drugs in small animals. (2019/01–2019/12, 805-C108-13)
  7. The suitability and accuracy of using an isolated rat liver perfusion model to predict drug hepatic clearance. (2020/01–2020/12, HAFGH-E-109019)
  8. Herbal–drug interactions in chronic cardiovascular disease: Schisandra Fructus influence on the pharmacokinetics of nifedipine. (2020/01–2020/12, HAFGH-E-109013)
  9. A novel opioid analgesic nalbuphine-6-glucuronide: Mechanism, pharmacokinetic and drug development study. (2020/08–2021/07, MOST 109-2320-B-016-011)
  10. A new sustained-release formulation of nalbuphine combined with acetaminophen to prolong pain-relief efficacy and reduce nalbuphine-induced dysphoria. (2021/01–2021/12, HAFGH-E-110020)
  11. Optimization of liver microsomal incubation to accurately predict drug metabolism from in vitro to in vivo extrapolation. (2021/01–2021/12, HAFGH-E-110013)
  12. What went wrong with the well-stirred model used to predict drug hepatic clearance over the past half-century? (2021/08–2022/07, MOST 110-2320-B-016-007)
  13. Application of 3D printing in microfluidic encapsulating technology to improve the oral bioavailability of penicillin. (2022/01–2022/12, 801GB111252)
  14. Physicochemical properties of drugs determining the accuracy of liver metabolic models in predicting plasma drug concentrations. (2022/01–2022/12, HAFGH-E-111015)
  15. The key factors affecting drug hepatic clearance: intrinsic clearance and plasma protein binding. (2022/01–2022/12, HAFGH-D-111012)
  16. A novel hepatic clearance model as the basis for evaluating liver metabolism of drugs: theoretical research and applicability analysis (1/2). (2022/01–2023/12, CMRPF1M0041)
  17. Precisely adjusting the hepatic clearance of highly extracted drugs using the modified well-stirred model. (2023/01–2023/12, MND-MAB-D-112113)
  18. A novel hepatic clearance model as the basis for evaluating liver metabolism of drugs: theoretical research and applicability analysis (2/2). (2023/01–2023/12, CMRPF1M0042)
  19. Re-examining the scale-up process in IVIVE to improve the prediction of human drug metabolism. (2023/01–2023/12, HAFGH-E-112016)
  20. Herb–drug interactions: the main active components of Xin-Yi-San in regulating CYP1A2. (2023/01–2023/12, HAFGH-D-112006)
🧾 Conference Papers
※ 可上下捲動瀏覽
  1. HJ Wang, WL Chang, MJ Lin, PW Huang, OYP Hu. New Finding of Nalbuphine Metabolites in Men: NMR Spectroscopy and UPLC–MS/MS Spectrometry Assays in a Pilot Human Study. 41st Military Medical Academic Conference, Taipei, Taiwan, Nov 2014.
  2. H-J Wang, C-H Hsiong, S-T Ho, M-J Lin, T-Y Shih, P-W Huang, O Y-P Hu. Commonly Used Excipients Modulate UGT2B7 Activity to Improve Nalbuphine Oral Bioavailability in Humans. 29th AAPS, Orlando, USA, Oct 25–29, 2015.
  3. H-J Wang, L-H Pao, C-H Hsiong, T-Y Shih, M-S Lee, O Y-P Hu. Dietary Flavonoids Modulate CYP2C to Improve Drug Oral Bioavailability and Their Qualitative/Quantitative Structure–Activity Relationship. 29th AAPS, Orlando, USA, Oct 25–29, 2015.
  4. Yan-Lun Chen, Tsan-Seng Hsiao, Hsin-Cheng Lin, Hong-Jaan Wang. The Synergistic Effects of Pain Relief Exerted from the Combination of Morphine, Diclofenac and Acetaminophen. 43rd Military Medical Academic Conference, Taipei, Taiwan, Nov 2016.
  5. H-J Wang, Y-L Chen, O Y-P Hu. Potent Analgesic Effect of Nalbuphine-6-Glucuronide: Chemical Synthesis, Pharmacokinetic Assessment, and Antinociceptive Evaluation. 31st AAPS, San Diego, USA, Nov 11–15, 2017.
  6. H-J Wang (Invited Speech). What’s wrong with the well-stirred model in predicting drug hepatic clearance? 2nd Joint Academic Annual Meeting of Pharmaceutical Society of Taiwan, Taipei, ROC, Nov 08, 2020.
  7. Hsin-Chung Cheng, An-Jun Zheng, Shu-Hao Hsu, Hsin-Yin Cheng, Tian-You Zhang, Ren-Jong Liang, Hong-Jaan Wang. Preliminary Evidence of Modified Well-stirred Model in Prediction of Hepatic Clearance. 49th Military Medical Academic Conference, Taipei, Taiwan, Nov 2022.
🧪 Laboratory Introduction
🧩 Short Biography
Dr. Hong-Jaan Wang is currently the Dean and Professor of the College of Pharmacy at the National Defense Medical University (NDMU), Republic of China. He earned his B.S. and M.S. degrees from the School of Pharmacy, and his Ph.D. from the Graduate Institute of Life Sciences at the National Defense Medical Center (former name of NDMU). Dr. Wang’s research focuses on pharmacokinetics and drug metabolism. He has published numerous peer-reviewed papers in pharmaceutical sciences and holds two formulation patents. His notable achievements include the development of an oral dosage form of a non-controlled opiate, which was previously available only as an injectable preparation. His research activities encompass formulation development, drug metabolite identification, analytical method establishment for drug quantification, and pharmacokinetic characterization. In addition to his academic role, Dr. Wang serves as a scientific consultant for Sinew Pharma Inc. and TheratOcular Biotek Co., providing expertise in new drug development and clinical research. He also contributes to public service as the Convener and Editor of the Chinese Pharmacopoeia Compilation Advisory Council.
🎯 Research Focus
1️ Novel Therapeutic Development for Nonalcoholic Fatty Liver Disease (NAFLD)
2️ Development of New Formulations for Opioid Analgesics
🧠 Training & Career
Our laboratory provides comprehensive training across multiple areas of pharmaceutical research, including in vivo, in vitro, and ex vivo drug concentration monitoring, metabolite identification, pharmacokinetic analysis, molecular biology studies, medicinal chemical synthesis, and the development of novel drug delivery systems and dosage forms. Through this intensive training, students are well prepared to pursue advanced degrees or careers in pharmaceutical R&D, regulatory affairs (IND & NDA), new drug applications under the 505(b)(1), 505(b)(2), and 505(j) pathways, as well as clinical trial management in governmental agencies and pharmaceutical or biotechnology industries.
📣 Recruitment
We warmly welcome motivated individuals from diverse academic backgrounds to join our laboratory. Given the interdisciplinary nature of our research, prior pharmaceutical training is not required. If you are passionate about drug development and translational research, we encourage you to take the next step. Join us at the College of Pharmacy, National Defense Medical University — Lab 9304R is looking forward to working with you.
🔬 Current Research (Figures)
Drug Metabolism Studies of Cytochrome P450 (CYP450) and UDP-Glucuronosyltransferases (UGTs)【Figure 1】
In Vitro and In Vivo Metabolic Profiling of the Opioid Analgesic Nalbuphine【Figure 2】
Development of a Novel Oral Nalbuphine Formulation【Figure 3】
【Figure 1】Workflow of Enzyme-Mediated Drug Metabolism Studies：
酵素代謝研究流程圖
【Figure 2】Nalbuphine Metabolic Pathway：
納布芬代謝模式圖
【Figure 3】 PK/PD Studies of an Oral Nalbuphine Formulation：
納布芬口服劑型之藥動學及藥效學研究圖
🎬 Lab Highlights
  • Views:491
  • Update Date:2026-03-17
  • Contact Us